ERCC1 and lung adenocarcinoma: Therefore, we consider that H19 may play a major role in overcoming acquired resistance to cisplatin as a novel epigenetic regulator in lung adenocarcinoma such as ERCC1 [44], and sensitizing H19 might be an efficient therapeutic intervention in cisplatin resistance of lung adenocarcinoma.